OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Durham, NC-Results of a 9-month randomized, dose-masked, multicenter clinical trial of a fluocinolone acetonide sustained drug delivery system to treat posterior uveitis resulted in significant gains for the eyes that received implants when compared with fellow eyes that did not receive implants, said Glenn J. Jaffe, MD.
Related Content: